Current antipsychotic therapies can address the positive symptoms, but the negative and cognitive symptoms remain poorly managed, if at all, and are key predictors of functional disability. A large number of anatomical, molecular, genetic, preclinical behavioral and human clinical studies have provided strong evidence that agents able to enhance cholinergic transmission or activate muscarinic acetylcholine receptors (mAChRs, M1- M5), notably M1, have exciting therapeutic potential for the treatment of the positive, negative and cognitive symptoms of schizophrenia as well as cognitive dysfunction in other CNS disorders. However, previous compounds developed to selectively activate M1 receptors have failed in clinical development due to a lack of true specificity for M1 and adverse effects associated with activation of other mAChR subtypes (M2-M5). Furthermore, the lack of highly selective compounds has made it impossible to definitively determine whether the behavioral and clinical effects of these compounds are mediated by M1. Mechanistically, it is intriguing that selective M1 activation fits well with the glutamate hypothesis, or NMDA (N-methyl-D-aspartate) hypofunction hypothesis of schizophrenia, as both M1 and the NR1a NMDA subunit are co-localized at specific postsynaptic sites, and activation of M1 by orthosteric mAChR agonists, and more recently, highly selective M1 allosteric agonists and M1 positive allosteric modulators (PAMs), developed during the previous funding period, potentiate NMDA currents in hippocampal slices, display robust efficacy in preclinical antipsychotic rodent models and improve cognitive performance in multiple hippocampal-driven models. When this grant was initially funded four years ago, no truly selective M1 activators existed with the requisite mAChR selectivity, ancillary pharmacology or DMPK properties to study the role of selective M1 activation in vivo. Thus, during the previous funding period, we were highly successful in developing a vast array of highly selective M1 activators (both functionally M1 selective agonists and M1 PAMs representing multiple chemotypes) with unprecedented, clean ancillary pharmacology and DMPK profiles enabling in vivo studies to be performed via the chemical optimization of hits from a functional M1 high-throughput screen. Based on ligand-biased signaling phenomena, in order to definitively evaluate selective M1 activation in the context of NMDA hypofunction models of schizophrenia, we must develop a suite of M1 ligands with comparable DMPK properties that activate all M1-mediated pathways, as well as select, specific pathways in vivo. This research has direct relevance to the mission of NIMH and has the potential to impact human health directly. Our goal for this project is to develop, in parallel, selective M1 allosteric agonists and M1 positive allosteric modulators with acceptable profiles for preclinical and ultimately clinical development that may lead to a new drug for the treatment of the positive, negative and cognitive symptoms of schizophrenia.

Public Health Relevance

We have been highly successful in developing a vast array of highly selective M1 activators (both functionally M1 selective agonists and M1 PAMs representing multiple chemotypes) with unprecedented, clean ancillary pharmacology and DMPK profiles enabling in vivo studies to be performed via the chemical optimization of hits from a functional M1 high-throughput screen. Due to ligand-biased signaling phenomena, in order to definitively evaluate selective M1 activation in the context of NMDA hypofunction models of schizophrenia, we must develop a suite of M1 ligands with comparable DMPK properties that activate all M1-mediated pathways, as well as select, specific pathways in vivo. These studies could lead to new therapeutic agents to address the negative and cognitive symptoms of schizophrenia.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
2R01MH082867-06
Application #
8503224
Study Section
Special Emphasis Panel (DDNS)
Program Officer
Driscoll, Jamie
Project Start
2008-05-20
Project End
2018-05-31
Budget Start
2013-08-01
Budget End
2014-05-31
Support Year
6
Fiscal Year
2013
Total Cost
$390,000
Indirect Cost
$140,000
Name
Vanderbilt University Medical Center
Department
Neurosciences
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Rook, Jerri M; Abe, Masahito; Cho, Hyekyung P et al. (2017) Diverse Effects on M1 Signaling and Adverse Effect Liability within a Series of M1 Ago-PAMs. ACS Chem Neurosci 8:866-883
Bender, Aaron M; Weiner, Rebecca L; Luscombe, Vincent B et al. (2017) Discovery and optimization of 3-(4-aryl/heteroarylsulfonyl)piperazin-1-yl)-6-(piperidin-1-yl)pyridazines as novel, CNS penetrant pan-muscarinic antagonists. Bioorg Med Chem Lett 27:3576-3581
Bender, Aaron M; Weiner, Rebecca L; Luscombe, Vincent B et al. (2017) Synthesis and evaluation of 4,6-disubstituted pyrimidines as CNS penetrant pan-muscarinic antagonists with a novel chemotype. Bioorg Med Chem Lett 27:2479-2483
Balu, Darrick T; Li, Yan; Takagi, Shunsuke et al. (2016) An mGlu5-Positive Allosteric Modulator Rescues the Neuroplasticity Deficits in a Genetic Model of NMDA Receptor Hypofunction in Schizophrenia. Neuropsychopharmacology 41:2052-61
Ghoshal, A; Rook, J M; Dickerson, J W et al. (2016) Potentiation of M1 Muscarinic Receptor Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse Model. Neuropsychopharmacology 41:598-610
Dean, Brian; Hopper, Shaun; Conn, P Jeffrey et al. (2016) Changes in BQCA Allosteric Modulation of [(3)H]NMS Binding to Human Cortex within Schizophrenia and by Divalent Cations. Neuropsychopharmacology 41:1620-8
Lindsley, Craig W; Emmitte, Kyle A; Hopkins, Corey R et al. (2016) Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors. Chem Rev 116:6707-41
Grannan, Michael D; Mielnik, Catharine A; Moran, Sean P et al. (2016) Prefrontal Cortex-Mediated Impairments in a Genetic Model of NMDA Receptor Hypofunction Are Reversed by the Novel M1PAM VU6004256. ACS Chem Neurosci 7:1706-1716
Panarese, Joseph D; Cho, Hykeyung P; Adams, Jeffrey J et al. (2016) Further optimization of the M1 PAM VU0453595: Discovery of novel heterobicyclic core motifs with improved CNS penetration. Bioorg Med Chem Lett 26:3822-5
Han, Changho; Chatterjee, Arindam; Noetzel, Meredith J et al. (2015) Discovery and SAR of muscarinic receptor subtype 1 (M1) allosteric activators from a molecular libraries high throughput screen. Part 1: 2,5-dibenzyl-2H-pyrazolo[4,3-c]quinolin-3(5H)-ones as positive allosteric modulators. Bioorg Med Chem Lett 25:384-8

Showing the most recent 10 out of 40 publications